Kornimate/medical-research-clean huggingface dataset:
impact of anti-citrullinated protein antibody status on treatment response and treatment persistence in participants with rheumatoid arthritis (ra) who are treated with abatacept or tumor necrosis factor inhibitors in australia

Conditions: Rheumatoid Arthritis

Summary: an observational study assessing the impact of anti-citrullinated antibody (acpa) in rheumatoid arthritis (ra) participants who have received abatacept or tumour necrosis factor inhibitors (tnfi) from the optimising patient outcome in australian rheumatology (opal) registry


Eligibility criteria:
inclusion criteria: * diagnosed with rheumatoid arthritis * have a baseline acpa recorded * received either abatacept or a tnfi (adalimumab, certolizumab, etanercept or golimumab) during the sample selection window 1 august 2006 to 30 june 2017 exclusion criteria: * patients who have died * patients with concomitant inflammatory diseases (e.g. ankylosing spondylitis, psoriatic arthritis, crohn's disease, ulcerative colitis) * patients who have no visit data recorded (even if medication data is available) other protocol defined inclusion/exclusion criteria could apply
community-based implementation of online emreg

Conditions: Traumatic Brain Injury; Emotion Regulation

Summary: this is a hybrid type iii implementation-effectiveness trial; this study design blends elements of implementation and clinical effectiveness research, with the primary aim of determining the utility of an implementation strategy and a secondary aim of assessing clinical outcomes associated with the implementation trial. consistent with best practices for this type of design, the study team will conduct a randomized test of the effect of implementation strategy on effective delivery of the online emreg intervention in clinical practice. specifically, the study team will compare standard training (a 3-hour on-demand training workshop) to extended training, (a 3-hour on-demand training workshop with 3 months of bi-weekly consultation). the research team's primary aim is to determine the optimal strategy to train clinicians in effectively delivering online emreg, and secondary aim is to assess patient improvement per clinician-administered ders. outcome measures will be assessed via self-report surveys, performance evaluations (via role-plays), and tracked clinician participation and fidelity. study participation is expected to last up to 18 months.


Eligibility criteria:
inclusion criteria: * licensed psychologist, social worker, or mental health counselor. * training and experience in cbt, the framework for emreg. * experience working with people with tbi. * experience providing group treatment. * a computer and internet to conduct group treatment via telehealth. * actively treating ≥3 patients with tbi who are appropriate for emreg (have emotion regulation difficulties based on clinician assessment). * amenable to study tasks (e.g., completion of training, consultation, performance based role-play, data collection). * not previously trained in emreg. * proficient in english. exclusion criteria: * not willing to conduct group treatment via telehealth. * non-english speaking.
short-term effects of ischemic compression applied in addition to classical massage in the treatment of trigger points

Conditions: Trigger Point Pain, Myofascial

Summary: the aim of our study was to investigate the short-term effects of ischemic compression applied in addition to classical massage for the treatment of myofascial trigger points on the upper trapezius muscle in women on pain, functionality and quality of life.

the aim of our study was to investigate the short-term effects of ischemic compression applied in addition to classical massage in the treatment of myofascial trigger points on the upper trapezius muscle in women on pain, functionality and quality of life. "visual analog scale (vas)" was used for pain assessment of individuals who accepted to participate in the study; universal goniometer was used to measure active neck active range of motions (arom) for functionality; and "short form-36 (sf-36)" was used for quality of life. then, the participants were randomly divided into two groups \[group 1: classical massage group; group 2: classical massage + ischemic compression group\]. classical massage was applied to both groups three times a week for two weeks, and ischemic compression was applied to group 2 in addition to classical massage. at the end of the treatment period, the participants were re-evaluated in terms of vas, neck arom and sf-36 scores.statistical analysis will be performed with spss 24.0 program. if the data is parametric, paired sample t-test will be used for within-group evaluation; independent sample t-test will be used for between-group evaluation. if the data is non-parametric, wilson test will be used for within-group evaluation and mann whitney u test will be used for between-group evaluation.

Eligibility criteria:
inclusion criteria: * being between the ages of 20-50 * having a myofascial trigger point detected in the upper trapezius muscle for at least two weeks * being a student or staff of halic university * being literate exclusion criteria: * having a history of cervical surgery * having a malignant disease * pregnancy * menopause * having cooperation problems
impact of neck inspiratory muscle activation during sleep in icu patients after a covid 19 ards

Conditions: ARDS; COVID-19

Summary: most patients in intensive care units (icus) experience severe sleep disruption. sleep disruption and sleep alteration may have an influence on the ability to breathe spontaneously. but, the cause of altered sleep remains unknown. previous studies have shown that decreasing nocturnal respiratory muscle activity through mechanical ventilation might improve sleep quality. nocturnal respiratory muscle activity may be one of the potential factor which contribute to alter sleep in the icu. therefore, the aim of this study is to analyse the presence of nim activation during the night and it's consequence in an icu population with the same pathology (covid 19 ards).

sleep alteration is a common problem among ventilated icu patient. about one third of the patient have abnormal eeg pattern which cannot be scored by using the aasm standard criteria. patients experience marked fragmentation, absence of deep sleep, and rem sleep is decreased, . it has been shown that sleep deprivation has a negative impact on respiratory muscle endurance. so a good sleep is essential when the respiratory system is being challenged, as in the icu during the weaning period. indeed, in the icu, patients with altered sleep, had a markedly longer weaning duration than in patients with normal sleep, and are more likely to fail a spontaneous breathing trial. many factors may influence the quality of sleep in the icu (noise, medication, mechanical ventilation ...) but few studies have focus on the cause of this altered sleep, and the cause of altered sleep remains unknown. previous studies have shown that decreasing nocturnal respiratory muscle activity through mechanical ventilation might improve sleep quality. mechanical ventilation can decrease the charge imposed on the respiratory pump, and allows muscle to rest. indeed, when the charge is too high (for example after an ards during the weaning period), the diaphragm may be overloaded, and there could be a greater involvement of other inspiratory muscles in breathing. in other pathological condition, the neck inspiratory muscle activity is increased (e.g. copd, amyotrophic lateral sclerosis), and sometimes this activity persist during sleep with marked degradation in sleep architecture. nocturnal respiratory muscle activity may be one of the potential factor which contribute to alter sleep in the icu. ttherefore, the aim of tis study is to analyse the presence of nim activation during the night and it's consequence in an icu population with the same pathology (covid 19 ards).

Eligibility criteria:
inclusion criteria: * patient above 18 year-old admitted to intensive care unit * covid-19 assessed by pcr on nasopharyngeal swab or pulmonary sample * oro-tracheal intubation for mechanical ventilation exclusion criteria: * guardianship or curatorship * prisoners * no health insurance * pregnancy

Keywords: neck inspiratory muscle (=nim) sleep intensive care unit ards
mini invasive endomicroscopy of the pleura for malignancies diagnosis

Conditions: Pleural Diseases; Pleural Neoplasms

Summary: recently, probe based confocal laser endomicroscopy showed to be able to distinguish malignant from benign pleura during medical thoracoscopy. however the clinical usefulness of this new tool remains to be determined. the investigators believe that pcle could be part of mini invasive pleural disease management and could be used during thoracentesis in order to increase the diagnostic yield of this procedure. the investigators are starting a prospective trial to recruit patients referred for medical thoracoscopy to the endoscopy unit. first, the pcle probe will be introduced through the boutin's needle or the thoracentesis catheter, just before the thoracoscopy, in order to investigate the pleural pcle features and to identify or exclude malignant infiltration. second those features will be compared to the pcle acquisition obtained during the medical thoracoscopy (the probe is introduced through the working chanel of the thoracoscope), under visual control. in order to compare the invasive and mini invasive acquisition, 10 criteria will be prospectively assessed.third, these features will be compared to the histological samples performed during thoracoscopy. finally, the interpretation of different investigators will be compared. the 10 criteria are presented below: 1. abnormal tissular architecture no: correct identification of the previously described normal pleura characteristics yes: identification of cellular/tissular structures which are not known to correspond to normal pleura (cellular clusters or dark clumps, glands, cells cordons, dysmorphic cells, papillar distribution....) 2. cellular homogeneity is size, shape and fluorescence, as subjectively assessed by the investigator yes no 3. mean cellular size: small: \ 20µm 4. cellular density (with reference to the chia seed sign) low (lower than the chia seed sign) moderate high 5. dysplastic vessels: yes: (vascular leaks, tortuous or giant vessels) no: no dysplasia 6. vascular density (on a full optical area) low: 0 -2 vessels moderate: 3 - 4 vessels high: \> 4 vessels 7. organized or anarchic connective fibers anarchic: coarse fibers, irregular in shape, without well-defined architecture organized : regular in shape and direction, well defined architecture. 8. chia seed sign on a full optical areal yes no


Eligibility criteria:
inclusion criteria: * every patient referred to the endoscopy unit for medical thoracoscopy exclusion criteria: * pregnancy * known allergy to the fluorescein

Keywords: probe based confocal laser endomicroscopy
feasibility study of neoadjuvant chemotherapy modified folfox6 for resectable liver metastases of colorectal cancers

Conditions: Colorectal Cancer; Liver Metastasis

Summary: the purpose of this study is to evaluate the safety of liver resection for metastatic, resectable lesions from colorectal cancers after systemic chemotherapy.


Eligibility criteria:
inclusion criteria: 1. histologically diagnosed as colorectal adenocarcinomas, including cecal, appendiceal, and anal canal cancers. 2. liver lesions are measurable by spiral ct or spio-mri scans. 3. extrahepatic lesions include lung metastases which can be resected curatively. 4. curative resection for metastatic lesions can be performed with residual hepatic functions preserved. 5. no prior treatment histories for liver lesions, including l-ohp regimens, hepatectomy, hepatic arterial infusion, mct, or rfa 6. no evidence of chronic hepatic diseases which affect systemic chemotherapy and/or surgical resection 7. performance status (ecog): 0-1 8. vital organ functions, including hematopoietic, cardiac, respiratory and renal functions, are preserved. exclusion criteria: excluded are cases with conditions as below: 1. peritoneal or pleural fluid retention to be drained. 2. multiple malignancies to be treated. 3. peripheral neural disturbances. 4. active infectious diseases. 5. severe watery diarrhea. 6. mental disturbances. 7. treatment history of continuous, oral or intravenous steroid therapy. 8. previous history of ischemic heart diseases. 9. coexistent severe diseases including pulmonary fibrosis, interstitial pneumonia, ileus, uncontrollable diabetes, cardiac dysfunction, hepatic failure, or renal failure. 10. pregnant. 11. previous history of severe drug-induced allergy.

Keywords: neoadjuvant chemotherapy metastatic liver lesions from colorectal cancers
influence of a brief intervention on crc screening

Conditions: Colorectal Cancer

Summary: qualitative data were collected from 5 general practionners (gps) focus groups, 24 patient interviews and 35 recorded consultations from 9 gps to explore colorectal cancer (crc) screening in france the qualitative data indicated that improvement was needed in patient-centered communication. educational material was developed based on these triangulated data with two different scenarios to improve communication with patients: one for a compliant patient, another for a non compliant patient the hypothesis is that a brief intervention on gps can improve the patients' participation rate to colorectal screening method : cluster randomized control trial (cluster unit : gps practices) with a brief intervention on a randomized population of gps in the district of val d'oise inclusion criteria: gps with a practice in the district of val d'oise and active in the colorectal mass screening

a cluster randomized controlled parallel groups study was conducted in the val d'oise department in france all practices of the val d'oise department were eligible to participate. among 585 practices, an independent biostatistician randomized 50 practices per arm in october 2011 according to a computer generated randomization list.two team members phone called all the gps of the randomized practices. gps from practices in the control group are asked to continue their usual care, as if they were not participating in this trial. gps of both groups had to send their patients list to the research team to calculate their eligible population. they were also asked to list all the gfobt delivered during the six months period of the study. gps of the intervention group received a four hours educational training focused on patients' centered care.

Eligibility criteria:
inclusion criteria: inclusion of gps practices: all gps practices of the val d'oise department in france were eligible to participate gps using complementary therapies occasionally were allowed to participate exclusion criteria: exclusion of gps practices : practices were excluded when doctors used exclusively complementary therapies (acupuncture therapy, homeopathy....) -

Keywords: cancer, crc screening, communication
a phase 2 study of tomudex & iressa as second line chemotherapy in subjects with colorectal carcinoma

Conditions: Colorectal Cancer

Summary: the primary objective of this study is to compare the activity of raltitrexed and zd1839 versus raltitrexed alone as second line chemotherapy in subjects with colorectal carcinoma by estimating progression free survival (pfs) in each treatment arm.


Eligibility criteria:
inclusion criteria: * male or female, aged 18 to 75 years, inclusive * histologically-confirmed metastatic colorectal carcinoma; measurable lesion according to the response evaluation criteria in solid tumours (recist) * relapsed after treatment with a fluoropyrimidine-based chemotherapy * prior chemotherapeutic regimen for metastatic or locally advanced disease with an interval of at least 4 weeks between the last administration of chemotherapy an the first administration of study treatment * eastern cooperative oncology group (ecog) performance status of 0 to 2 * life expectancy of at least 12 weeks exclusion criteria: * known severe hypersensitivity to raltitrexed or any of the excipients of this product * known severe hypersensitivity to raltitrexed or any of the excipients of this product * active infection or uncontrolled diarrhoea * cerebral metastasis or meningeal carcinomatosis * any evidence of clinically active interstitial lung disease (patients with chronic stable radiographic changes who are asymptomatic need not be excluded) * simultaneous antitumoral treatment * radiotherapy within 2 weeks before entry into the study * other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ * any unresolved chronic toxicity greater than common toxicity criteria (ctc) grade 2 from previous anticancer therapy (except alopecia) * significant clinical disorder or laboratory finding (leukocyte count less than 3.0 x 109 /litre (l) or platelets less than 100 x 109 /l; serum total bilirubin more than 2.0 mg/dl; as judged by investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease); creatinine clearance ≥ 65ml/min (according to cockcroft-gault formula); alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 2 times the upper limit of the reference range (ulrr) if no demonstrable liver metastases, or greater than 5 times the ulrr in the presence of liver metastases) * pregnancy or breast feeding (women of child-bearing potential) * concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or st john's wort; * treatment with a non- approved or investigational drug within 30 days before day 1 of study treatment

Keywords: colorectal carcinoma advanced disease
manta study: avastin versus lucentis in age related macular degeneration

Conditions: Age Related Macular Degeneration

Summary: angiogenesis plays a key role in the development of choroidal neovascularizations (cnv) in age-related macular degeneration. vascular endothelial growth factor (vegf) is the most important factor involved in this angiogenetic processes in the eye. this forms the basis for new therapeutic interventions in exudative amd. currently two drugs have been approved by the fda and one drug is used off-label. all these drugs are administered intravitreally. the present study aims to directly compare the effects ranibizumab and bevacizumab in a randomized controlled study in patients with neovascular amd.


Eligibility criteria:
inclusion criteria: * age ≥ 50 years * active primary or recurrent subfoveal lesion with cnv secondary to amd exclusion criteria: prior treatment with any intravitreal drug in the study eye * prior treatment with verteporfin photodynamic therapy in the study eye * prior treatment with systemic bevacizumab * prior treatment with any intravitreal durg or verteprofin photodynamic therapy in the nonstudy eye within the 3 moths before the study entry * laser photocoagulation within 1 month before study entry in the study eye * previous participation in any clinical trial within 1 month before the entry of the study * subfoveal fibrosis or atrophy in the study eye * cnv in either of the two eye due to causes other than amd such as histoplasmosis or pathologica myopia * retinal pigment epithelial tear involving the macula in the study eye * any concurrent intraocular condition in the study eye that could either require medical or surgical intervention during the 12 month study period or that could contribute to a loss of best corrected visual acuity over the 12 months study period (e.g. diabetic retinopathy, cataract, uncontrolled glaucoma). the decision on exclusion is to be based on the opinion of the local principal investigator. * active intraocular inflammation * vitreous hemorrhage in the study eye

Keywords: age related macular degeneration ranibizumab-lucentis bevacizumab-avastin
development of a molecular diagnosing platform for relieving periodontal symptoms

Conditions: Periodontal Diseases; Peri-Implantitis

Summary: more than ninety percent of adults in taiwan are suspected to carry periodontal disease, which causes bad breath, swollen and bleeding gums, plaque and even tooth loss. half of the patients, however, are ignorance these clinical syndromes because of no obvious pain. in this study, the investigators selected six periodontal disease-associated bacteria strains, including porphyromonas gingivalis (pg), fusobacterium nucleatum (fn), actinobacillus actinomycetemcomitans (aa), tannerella forsythia (tf), treponema denticola (td) and prevotella intermedia (pi) as diagnostic markers. using real-time pcr and maldi biotyper, the investigators will establish the database of oral microorganisms in taiwanese people, providing periodontal disease clinical markers of high-risk groups and the basis for personal medicine of therapy in the future.


Eligibility criteria:
inclusion criteria: 1. age≧25 2. 3≦periodontal screening and recording≦4 3. 16 natural teeths and 6 front teeth at lesat 4. gi≧1.25 5. pi≧2 exclusion criteria: 1. people who have oral lesion, dental braces, denture, mouthwash allergy, or serious systemic disease 2. people who have ever eaten antibiotics and anti-inflammatory drugs over the last 6 months 3. people who have ever eaten immunosuppressive drugs, antiepileptic drugs, antihypertensive drugs, or anticoagulant 4. pregnant women or the woman who eat birth control pills
household transmission investigation study for covid-19 in tropical regions

Conditions: Coronavirus Infections; Severe Acute Respiratory Syndrome; SARS-CoV Infection

Summary: this study is a interventional study that present minimal risks and constraints to evaluate the presence of novel coronavirus (sars-cov-2) or antibodies among individuals living in households where there is a confirmed coronavirus case in order to provide useful information on the proportion of symptomatic forms and the extent of the virus transmission in tropical regions such as french guiana, guadeloupe and new-caledonia.

this study is a interventional study that present minimal risks and constraints to evaluate the presence of novel coronavirus (sars-cov-2) or antibodies among individuals living in households where there is a confirmed coronavirus case in order to provide useful information on the proportion of symptomatic forms and the extent of the virus transmission in tropical regions such as french guiana, guadeloupe and new-caledonia. subjects will be assessed (questionnaires and sampling) in their homes. subjects will be asked to attend study visits at days 0, 7, 14, 21, 28, 60, 90, 180 and 360. the primary objective of the study is to evaluate the rate of intra-household secondary transmission of the virus.

Eligibility criteria:
inclusion criteria: * primary case: laboratory-confirmed coronavirus sars-cov-2 infection by polymerase chain reaction (pcr), or family contact in french guiana and guadeloupe: person who lived in the same household as the primary case of covid-19 when the primary case was symptomatic. a household is defined as a group of people (2 or more) living in the same accommodation (excluding residential institutions such as boarding schools, dormitories, hostels, prisons, other communities hosting grouped people), or close contact in new-caledonia: any individual who was in contact with a primary case, in his/her family/living environment, work/school, friends/leisure or means of transport, when the primary case was symptomatic or presymptomatic, * affiliated or beneficiary of a social security system * informed consent prior to initiation of any study procedures from subject (or legally authorized representative) * state of health compatible with a blood sample as defined in the protocol. exclusion criteria: * inability to consent * person under guardianship or curatorship * known pathology or a health problem contraindicated with the collect of blood sample.

Keywords: sars-cov-2 covid-19 serology french guiana